Airwallex partners with University of Melbourne to forge Australia’s future tech leaders

MELBOURNE, Australia--(BUSINESS WIRE)--Global fintech Airwallex has embarked on a pivotal partnership with the University of Melbourne, which will help build the next generation of Australian tech leaders. With a total investment from Airwallex of more than A$3 million, the partnership is aimed at increasing access, exposure and career opportunities for technology students, and in turn, growing the pool of future tech talent in Australia. The partnership will run over the next three years (2022 - 2025), and builds on Airwallex’s long-term relationship with the University, which is where the four Airwallex co-founders first met. University of Melbourne’s Engineering and Information Technology students will be considered for a range of opportunities across multiple programs, including: Airwallex Excellence in Technology Scholarships: 42 financial scholarships, valued at up to A$15,000 per annum, will be offered across the three years for gifted and promising students in Bachelor or Masters programs. Scholarship recipients will be given priority consideration for internships at Airwallex. The Opportunity Fund: For students experiencing financial hardship, this fund will provide one-off payments for up to 100 students to support their studies, and is available throughout 2022 and 2023 to both domestic and international students. Student Enrichment Plan: A series of special activations, awards and facilities to foster innovation amongst students and alumni. This will include hackathons, guest lectures and talks from Airwallex leaders at key University events such as the Endeavour Exhibition, which Airwallex has been involved with since 2019. Future Idea Fund: A plethora of initiatives to increase access and exposure to training and careers in technology. Airwallex and University of Melbourne staff and students will also have the opportunity to co-locate in the Melbourne Connect innovation precinct. Located in Parkville, Melbourne Connect brings together world-class researchers, industry leaders, start-ups, government representatives and students seeking to leverage research and emerging technologies to disrupt and transform society. As a nod to the founders who were running a cafe in Melbourne’s CBD when they started exploring ideas that would become Airwallex, the company will provide free coffee at Melbourne Connect for students through the partnership. The partnership between Airwallex and the University of Melbourne will expand opportunities available for students, and in turn, grow the pool of future tech talent in Australia. This initiative comes at a time when the tech talent shortage continues to impact Australian businesses. The Tech Council of Australia has forecasted that Australia will need 653,000 additional people in tech jobs by 2030 to fuel the nation’s economic growth1. Airwallex Co-founder, CEO, and University of Melbourne alum Jack Zhang, said, “Since our inception, Airwallex has strived to create opportunities for exponential career growth and development. Our partnership with the University of Melbourne marks a significant step-change in our contribution to building the tech leaders of tomorrow. It’s an honour and a privilege to be in a position to give back to the community that's been a part of the Airwallex story from day one. “Airwallex was founded by looking beyond what’s possible, and we want to empower students to do the same. Whether through scholarships or grants, Airwallex guest lectures or events, our partnership aims to drive innovation and provide meaningful support to the next generation of technology professionals and leaders. “We understand deeply the tech talent challenges facing businesses today. By providing students with opportunities and support from inside the sector, this partnership aims to grow the local talent pool and ultimately, strengthen Australia’s tech and startup ecosystem. I look forward to seeing the next generation of Australian tech leaders, entrepreneurs and innovators benefit from this partnership and make their mark in the world.” Dean of the University’s Faculty of Engineering and Information Technology Professor Mark Cassidy said the University was delighted with the new partnership. “It is very exciting to see alumni, such as Jack and his co-founders, achieve such success with their own business and be able to give back so generously to the next generation of technology professionals and Australia’s broader tech sector,” Professor Cassidy said. “The Airwallex scholarship and opportunity programs will make a real difference to our students’ ability to focus and continue with their studies each year, while the enrichment and idea programs will equip our students with the knowledge and mindset to become leaders in the workforce.” “This partnership exemplifies the University of Melbourne’s commitment to collaboration as a means of nurturing innovation. Bringing together world-class researchers and educators, industry and students, we can create an environment where great minds connect and incredible futures emerge.” “The Tech Council of Australia welcomes this exciting new partnership that will ensure more students gain crucial skills that will allow them better access to great Australian tech jobs. This partnership is a great example of the power of collaboration and how organisations can work together to improve and create new pathways to attract more students to consider and take up a career in tech,” said Tech Council of Australia CEO, Kate Pounder. About Airwallex Airwallex is the leading financial technology platform for modern businesses growing beyond borders. With one of the world’s most powerful payments and banking infrastructure, our technology empowers businesses of all sizes to accept payments, move money globally, and simplify their financial operations, all in one single platform. Established in 2015 in Melbourne, our purpose is to connect entrepreneurs, business builders, makers and creators with opportunities in every corner of the world. Today, Airwallex has a global footprint across Asia-Pacific, Europe, and North America. Find out more at www.airwallex.com. 1Referenced from Getting to 1.2 million jobs – Our roadmap to create a thriving Australian tech workforce, launched by the Tech Council of Australia in August 2022
http://dlvr.it/Sc1ggF

Celebrating BIPOC Small Businesses in Honor of Small Business Saturday

By Veronica Castillo Small Business Saturday is recognized and celebrated the Saturday after Thanksgiving. This is the day to celebrate and support small businesses in our own communities. In large cities, small businesses are the majority of the businesses. The Business Journal reports: New York City has about 560,000 small businesses, Los Angeles has about Read the full article...
http://dlvr.it/Sc113J

Global Medical Cannabis Global Market Insights 2022: Analysis and Forecast to 2027 by Manufacturers, Regions, Technology, Product Type – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Medical Cannabis Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering. This report describes the global market size of Medical Cannabis from 2017 to 2021 and its CAGR from 2017 to 2021, and also forecasts its market size to the end of 2027 and its CAGR from 2022 to 2027. For the geography segment, regional supply, demand, major players, price is presented from 2017 to 2027. The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc. For the competitor segment, the report includes global key players of Medical Cannabis as well as some small players. The information for each competitor includes: Company Profile Main Business Information SWOT Analysis Sales Volume, Revenue, Price and Gross Margin Market Share Types Segment: Dronabinol Nabilone Cannabidiol Cannabinol Scope Base Year: 2022 Historical Data: from 2017 to 2021 Forecast Data: from 2022 to 2027 Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Abbreviation and Acronyms Chapter 3 Preface 3.1 Research Scope 3.2 Research Sources 3.2.1 Data Sources 3.2.2 Assumptions 3.3 Research Method Chapter 4 Market Landscape 4.1 Market Overview 4.2 Classification/Types 4.3 Application/End Users Chapter 5 Market Trend Analysis 5.1 Introduction 5.2 Drivers 5.3 Restraints 5.4 Opportunities 5.5 Threats 5.6 Covid-19 Impact Chapter 6 Industry Chain Analysis 6.1 Upstream/Suppliers Analysis 6.2 Medical Cannabis Analysis 6.2.1 Technology Analysis 6.2.2 Cost Analysis 6.2.3 Market Channel Analysis 6.3 Downstream Buyers/End Users Chapter 7 Latest Market Dynamics 7.1 Latest News 7.2 Merger and Acquisition 7.3 Planned/Future Project 7.4 Policy Dynamics Chapter 8 Trading Analysis 8.1 Export of Medical Cannabis by Region 8.2 Import of Medical Cannabis by Region 8.3 Balance of Trade Chapter 9 Historical and Forecast Medical Cannabis Market in North America (2017-2027) 9.1 Medical Cannabis Market Size 9.2 Medical Cannabis Demand by End Use 9.3 Competition by Players/Suppliers 9.4 Type Segmentation and Price 9.5 Key Countries Analysis 9.5.1 United States 9.5.2 Canada 9.5.3 Mexico Chapter 10 Historical and Forecast Medical Cannabis Market in South America (2017-2027) 10.1 Medical Cannabis Market Size 10.2 Medical Cannabis Demand by End Use 10.3 Competition by Players/Suppliers 10.4 Type Segmentation and Price 10.5 Key Countries Analysis 10.5.1 Brazil 10.5.2 Argentina 10.5.3 Chile 10.5.4 Peru Chapter 11 Historical and Forecast Medical Cannabis Market in Asia & Pacific (2017-2027) 11.1 Medical Cannabis Market Size 11.2 Medical Cannabis Demand by End Use 11.3 Competition by Players/Suppliers 11.4 Type Segmentation and Price 11.5 Key Countries Analysis 11.5.1 China 11.5.2 India 11.5.3 Japan 11.5.4 South Korea 11.5.5 Southeast Asia 11.5.6 Australia Chapter 12 Historical and Forecast Medical Cannabis Market in Europe (2017-2027) 12.1 Medical Cannabis Market Size 12.2 Medical Cannabis Demand by End Use 12.3 Competition by Players/Suppliers 12.4 Type Segmentation and Price 12.5 Key Countries Analysis 12.5.1 Germany 12.5.2 France 12.5.3 United Kingdom 12.5.4 Italy 12.5.5 Spain 12.5.6 Belgium 12.5.7 Netherlands 12.5.8 Austria 12.5.9 Poland 12.5.10 Russia Chapter 13 Historical and Forecast Medical Cannabis Market in MEA (2017-2027) 13.1 Medical Cannabis Market Size 13.2 Medical Cannabis Demand by End Use 13.3 Competition by Players/Suppliers 13.4 Type Segmentation and Price 13.5 Key Countries Analysis 13.5.1 Egypt 13.5.2 Israel 13.5.3 South Africa 13.5.4 Gulf Cooperation Council Countries 13.5.5 Turkey Chapter 14 Summary For Global Medical Cannabis Market (2017-2022) 14.1 Medical Cannabis Market Size 14.2 Medical Cannabis Demand by End Use 14.3 Competition by Players/Suppliers 14.4 Type Segmentation and Price Chapter 15 Global Medical Cannabis Market Forecast (2022-2027) 15.1 Medical Cannabis Market Size Forecast 15.2 Medical Cannabis Demand Forecast 15.3 Competition by Players/Suppliers 15.4 Type Segmentation and Price Forecast Chapter 16 Analysis of Global Key Vendors GW Pharmaceuticals plc Medigrow Akanda Corp. Spectrum Cannabis Bedrocan Verve Dynamic TerraTech Corp. Cannabis Science Inc. Peak Pharmaceuticals Inc. Cannabis-Rx Inc Nemus Biosciences Inc. Gb Sciences Insys Therapeutics Alkem Laboratories Akorn Ascent Pharmaceuticals TEVA Greenwich Biosciences Cronos Group Aurora Cannabis Aphria Tilray Constellation Brands MedBox Inc. TerraTech Corp. Cannabis Science Inc. Phoenix Life Sciences International Limited. MGC Pharma For more information about this report visit https://www.researchandmarkets.com/r/hxys1t
http://dlvr.it/Sc033j

Ohio Board of Pharmacy Publishes Updated Patient & Caregiver Numbers for September 2022

OHIO:  The State of Ohio Board of Pharmacy published updated patient & caregiver numbers for September 2022.  These numbers include: 586,586 Recommendations 309,548 Registered patients 19,144 Patients with Veteran Status 20,446 Patients with Indigent Status 1,194 Patients with a Terminal Diagnosis 161,690 Patients with both an active registration and an active recommendation 286,462 Unique patients Read the full article...
http://dlvr.it/SbqKbC

Unified Cannabis Enforcement Taskforce Targets Illegal Indoor Cultivation In Industrial Warehouses In Southern California In Second Operation

CALIFORNIA: In continuing its aggressive crackdown against illegal cannabis operators threatening the environment, communities, public health, and the legal market, the Unified Cannabis Enforcement Taskforce (UCETF) took recent actions to shut down unlicensed indoor cultivation operations in large, industrial warehouses located in the San Fernando Valley. Led by the Department of Cannabis Control (DCC), California Read the full article...
http://dlvr.it/SbpxHX

Brightseed Introduces Bio 01™, the First Dietary Fiber with Bioactives to Support Gut Strength

SAN FRANCISCO--(BUSINESS WIRE)--Brightseed, the bioactive discovery company, announced today the launch of Brightseed Bio 01™, a novel dietary hemp fiber to support gut health formulated for use in food and beverages. Sourced from upcycled hemp hulls and formulated to optimize bioactive content, Brightseed Bio 01™ is the only dietary fiber on the market that contains two bioactive compounds that have shown the ability to support gut barrier integrity in preclinical studies. Brightseed Bio 01™ will debut at SupplySide West (SSW), held October 31 - November 4, 2022 in Las Vegas (booth #2075). Brightseed’s new ingredient will be showcased in a number of on-trend prototypes, including a first-to-market protein crisp ingredient, BioCrisp+, jointly developed by Brightseed and Puris, a leading supplier of plant-based proteins, starches and grains. “We’re thrilled to launch Brightseed Bio 01™, the first of many bioactive ingredients in Brightseed’s pipeline that will enable companies to innovate for health and bring science-backed solutions forward for consumers,” said Sofia Elizondo, co-founder and COO, Brightseed. “More than ever, people are turning to the food and beverage industry for proactive and personalized health solutions. Brightseed Bio 01™ is the latest demonstration of how Forager® A.I. is furthering our understanding of how bioactives found in nature are powerful catalysts to improve human healthspan.” Dietary fiber is an essential part of any healthy diet because of its ability to help maintain normal gut health. But today, only 5% of Americans consume the recommended daily intake. Brightseed Bio 01™ infuses food and beverage products with a unique combination of both dietary fiber and bioactives to support gut strength. The gut health benefits that distinguish Brightseed Bio 01™ were identified by Brightseed’s A.I. platform Forager®. Brightseed Bio 01™ contains two naturally occurring plant compounds, N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT), that help maintain gut barrier integrity, according to Brightseed's recently presented preclinical research.1 Clinical research studies are underway to validate this health effect. Forager® also identified hemp hulls as the richest known source of NCT and NFT. Hemp hulls are a rich source of dietary fiber that are largely a byproduct of hemp heart production, which Brightseed has upcycled to create Brightseed Bio 01.™ In addition, Brightseed Bio1™ offers a high concentration of dietary fiber, enabling manufacturers to easily achieve a good source of fiber content in their products. Formulated to optimize bioactive content to support overall gut health, Brightseed Bio 01™ can be easily integrated into cereals, granolas, nutrition bars and functional beverages, among other popular items. Brightseed will demonstrate their fiber’s unique attributes in several product prototypes at SSW, including the newly formulated Puris BioCrisp+ made with Brightseed Bio 01™. The crisp is designed for inclusion in cereals, bars and baked goods, where it will deliver delicious, nutrition-packed crunch with an excellent source of protein and good source of fiber. “Sustainability and innovation are the core of what we do at PURIS. Partnering with Brightseed on a crisp that revitalizes a fiber stream to create a complete plant protein encompasses what we see as the future of the plant-based space,” said Tyler Lorenzen, CEO, PURIS Proteins. Anna Gustafson, RDN and Business Development Executive at PURIS added, “Bioactives have been missing from American diets, and attention to their functions is the future of better-for-you products. PURIS is excited to partner with Brightseed on a novel protein crisp that targets the fiber deficit and rising consumer demand for gut health solutions.” “Puris is an ideal partner that is at the forefront of plant-based, sustainability-focused health innovation that solves challenges food companies face, and we’re thrilled to debut Brightseed Bio 01™ with them in a revolutionary protein crisp for immediate consumer product integration,” said Alina Slotnik, VP of Bioactives, Brightseed. “Brightseed Bio 01™ not only demonstrates how Forager® is rapidly translating insights into tangible products for the marketplace but offers a true evolution in the field of nutrition science to benefit consumer health.” For more about Brightseed Bio 01™, visit booth #2075 at SupplySide West 2022, October 31-November 4, or https://www.brightseedbio.com/bioactives 1. Bolster, Doug. “Impact of two novel plant bioactives on rescue of impaired gut barrier function using human primary cell intestinal epithelium.” Presented at International Society for Nutraceuticals and Functional Foods Annual Conference, October 2-5, 2022. https://isnffweb.meetinghand.net/projectData/921/webData/Program-Book.pdf About Bioactives Bioactives are small molecule compounds produced by plants, fungi, and microbes that grow in and adapt to environments that present a wide range of challenges to their survival. Bioactives also benefit the health of humans – they are the enlivening caffeine in tea, the powerful antioxidant lycopene in tomatoes or curcumin in turmeric, and they inform active ingredients in medicines like Taxol, aspirin and Metformin, the latter a first-line treatment for Type 2 diabetes derived from the French lilac flower. Science has long known that bioactives are critical to human health, yet the vast majority remain unknown and uncharted – often referred to as the “dark matter” of nutrition. Brightseed’s A.I., Forager®, discovers bioactives in nature and maps them to human health outcomes at a rate and accuracy that was previously impossible. About Brightseed Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Visit www.brightseedbio.com to learn more. About PURIS PURIS is the leading supplier of pea protein in North America. The family-owned company is leading the plant-based protein movement by making organic and non-GMO ingredients more functional, accessible, affordable, and nutrient-rich. PURIS develops the ingredients that fuel retail's biggest brands, from alternative meats to non-dairy milks and everything in between. The company's domestic end-to-end system ensures a wholesome journey from seed to solution. PURIS was recently named the most innovative
http://dlvr.it/SblPrc

High Tide Announces Launch of Its NuLeaf Naturals Multicannabinoid Products in Manitoba

CALGARY, Alberta--(BUSINESS WIRE)--High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, is pleased to announce that its Colorado-based subsidiary, NuLeaf Naturals (“NuLeaf”), has had its Full Spectrum Multicannabinoid oil and plant-based softgels with delta-9 tetrahydrocannabinol (“Delta 9”), cannabichromene (“CBC”), cannabidiol (“CBD”), cannabigerol (“CBG”) and cannabinol (“CBN”) listed for sale in Manitoba through the Manitoba Liquor & Lotteries Corporation (“MBLL”). The oil will be available in 1800 ml containers at a concentration of 12 mg/ml for each of the listed five cannabinoids, while the plant-based softgels will be available in packages of 120, each softgel containing 3 mg of each of the five listed cannabinoids. “I am delighted to announce that the highly anticipated NuLeaf Naturals Multicannabinoid products are now available for all licensed cannabis retailers to stock in Manitoba, Canada’s fifth most populous province. Listing these products across multiple Canadian provinces will ensure greater access to these unique multicannabinoid formulations for even more Canadian consumers. This announcement comes on the heels of NuLeaf Naturals products being listed with the Ontario Cannabis Store last week in Ontario, and we look forward to listing these groundbreaking products in additional Canadian provinces soon,” said Raj Grover, President and Chief Executive Officer of High Tide. “High Tide, through it’s well established international CBD brands that are at the forefront of cannabinoid science and are amongst the most searched brands online, according to Google Analytics, is committed to enhancing the quality and variety of CBD products available to Canadian consumers. Through constant innovation in our international CBD subsidiaries, we look forward to introducing even more cutting-edge cannabinoid products in Canada and beyond,” added Mr. Grover. About NuLeaf Naturals Founded in 2014 in Denver, Colorado, NuLeaf Naturals is one of America’s leading cannabinoid companies. Since inception, NuLeaf has been committed to creating the world’s highest quality cannabinoid products in their most pure and potent form. NuLeaf’s products are produced at a cGMP-certified facility enabling them to manufacture groundbreaking cannabinoid formulations while reaching beyond the highest levels of regulatory compliance. Their cannabinoid products are sold direct-to-consumer from their website and are also available at bricks-and-mortar stores across the U.S. NuLeaf is committed to creating safe, consistent, and effective products and has proudly received over 25,000 verified 5-star customer reviews through its e-commerce platform. For more information about NuLeaf, please visit www.nuleafnaturals.com. ABOUT HIGH TIDE High Tide is a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets. The Company is the largest non-franchised cannabis retail chain in Canada, with 141 current locations spanning British Columbia, Alberta, Saskatchewan, Manitoba and Ontario. The Company is also North America’s first cannabis discount club retailer, under the Canna Cabana banner, which is the single-largest cannabis retail brand in Canada, with additional locations under development across the country. High Tide’s portfolio also includes retail kiosks and smart locker technology – Fastendr™. High Tide has been serving consumers for over a decade through its established e-commerce platforms, including Grasscity.com, Smokecartel.com, Dailyhighclub.com, and Dankstop.com and more recently in the hemp-derived CBD space through Nuleafnaturals.com, FABCBD.com, BlessedCBD.co.uk, BlessedCBD.de, and Amazon United Kingdom, as well as its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide was featured in the Report on Business Magazine’s ranking of Canada’s Top Growing Companies in both 2021 and 2022 and was named as one of the top 10 performing diversified industries stocks in the 2022 TSX Venture 50™. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain while providing a complete customer experience and maximizing shareholder value. For more information about High Tide, please visit www.hightideinc.com and its profile pages on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Neither the TSX Venture Exchange (the “TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones (including, without limitation, proposed acquisitions); the Company’s future growth prospects and intentions to pursue one or more viable business opportunities; the development of the Company’s business and future activities following the date hereof; expectations relating to market size and anticipated growth in the jurisdictions within which the Company and NuLeaf may from time to time operate or contemplate future operations; expectations with respect to economic, business, regulatory and/or competitive factors related to the Company and NuLeaf or the cannabis industry generally; the market for the Company and NuLeaf’s current and proposed product offerings, as well as the Company and NuLeaf’s ability to capture market share; the Company’s strategic investments and capital expenditures, and related benefits; the distribution methods expected to be used by the Company to deliver its product offerings; the competitive landscape within which each the Company and NuLeaf operates and the Company and NuLeaf’s market share or reach; the performance of the Company’s business and the operations and activities of the Company; the Company adding the number of additional cannabis retail store locations the Company proposes to add to the Company’s business upon the timelines indicated herein, and the Company remaining on a positive growth trajectory; the Company
http://dlvr.it/Sbkv2J

ISAP2022: The 14th International Forum for Sustainable Asia and the Pacific “Strengthening Synergies Between Climate Change and Biodiversity: From Science to Policy to Action”

TOKYO--(BUSINESS WIRE)--The Institute for Global Environmental Strategies (IGES) will host the 14th International Forum for Sustainable Asia and the Pacific (ISAP2022). Held in Japan, ISAP is an annual forum that features a range of discussions on sustainable development in Asia and the Pacific through Plenary Sessions and Thematic Tracks. This year, the Plenary Sessions will be held on Monday, 28 November at Pacifico Yokohama, and Thematic Tracks will be held online from Tuesday, 29 November to Monday, 5 December. The overall theme of ISAP2022 is ”Strengthening Synergies between Climate Change and Biodiversity: From Science to Policy to Action”, focusing on integration across two of the world’s most pressing environmental challenges: climate action and biodiversity conservation. In addition, the world has recently seen some major geopolitical changes triggered by Russia's invasion of Ukraine, and discussions at ISAP this year will look at how these changes will impact future global environmental policies and what direction to take to meet the challenges we now face. ISAP2022 webpage: https://isap.iges.or.jp/2022/en/index.html We have seen the growth of communities related to research and policy on these issues, but these groups have often worked in separate siloes. Greater cooperation would help to identify integrated solutions to climate change and biodiversity. It would also help anticipate and find a balance on climate change and biodiversity trade-offs, which tend not to be discussed much. Recently, there has been growing engagement and communication between the international science and policy communities. Notably, in November 2022, the 27th Conference to the Parties (COP27) to the United Nations Framework Convention on Climate Change (UNFCCC) is being held. The negotiations at COP27 will have implications for biodiversity. By the same token, in December, the 15th Conference to the Parties (COP15) to the Convention on Biological Diversity (CBD) is likely to adopt a “post-2020 global biodiversity framework” (GBF) that will include tackling climate change as one of the elements for reducing threats to biodiversity. In addition, discussions on how to promote an integrated approach have been central to ongoing efforts to enhance cooperation between the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) and the Intergovernmental Panel on Climate Change (IPCC). To accelerate action in this ”decisive decade”, ISAP will host a wide variety of sessions to deepen discussions with not only policymakers, but also research and academic institutions, business practitioners and youth, aiming to secure as many options as possible for the future, so that we can continue to enjoy the Earth’s natural environment under a stable climate for years to come. Featured Speakers TANAKA Akihiko President, Japan International Cooperation Agency Sandrine DIXSON-DECLEVE, Co-President, The Club of Rome Chang Hoon LEE, President, Korea Environment Institute (KEI) FUJITA Kaori, Senior Deputy Editor, Nikkei ESG / Professor, Graduate School of Life Sciences, Tohoku University TAKEUCHI Kazuhiko President, Institute for Global Environmental Strategies (IGES) Dates Plenary Sessions: 28 November 2022 Thematic Tracks: 29 November – 5 December 2022 Venue Plenary Sessions: Pacifico Yokohama and online (Zoom) Thematic Tracks: Online (Zoom) Organiser Institute for Global Environmental Strategies (IGES) Language Japanese/English (Simultaneous translation) Dedicated ISAP Website & Registration https://isap.iges.or.jp/2022/en/index.html About the International Forum for Sustainable Asia and the Pacific (ISAP) The International Forum for Sustainable Asia and the Pacific (ISAP) is held annually to facilitate up-to-date discussions on sustainable development in Asia and the Pacific, with the participation of front-line experts and diverse stakeholders from international organisations, governments, business and NGOs, sharing knowledge and information with a wide range of practitioners. ISAP2022 webpage: https://isap.iges.or.jp/2022/en/index.html About the Institute for Global Environmental Strategies (IGES) The Institute for Global Environmental Strategies (IGES) is a collaborative research and outreach organisation working to accelerate the transition to a sustainable, resilient, shared and inclusive Asia-Pacific region, both across borders and within the world at large. Our strategic research and operations are defined by a mission—to drive action on the world’s most critical environmental and social challenges through the delivery of trusted expertise on sustainable development and resilience. IGES operates as an agent of change. Together with key international organisations, governments, academic institutes, business and civil society leaders, we seek to foster a world where planetary boundaries are fully respected, a green economy is flexibly implemented, and the well-being of people is steadily improved. In so doing we emphasise workable and inspired approaches to cross-cutting global development issues ranging from climate change, natural resources and ecosystems management, and sustainable consumption and production, among many others. The Institute—established in 1998 with support from the Japanese government and Kanagawa Prefecture—maintains its international headquarters in Hayama, Japan. With offices and local centres in Tokyo, Kansai, Kitakyushu, Beijing, Bangkok and New Delhi, IGES supports a regional and global network for ground-breaking sustainable development research and practice.
http://dlvr.it/SbfxQj

NJ-CRC to Hold In-Person Meetings

NEW JERSEY: The upcoming New Jersey Cannabis Regulatory Commission public meeting on Thursday, October 27 will be held in person at 44 South Clinton Avenue in Trenton at 1 p.m. The meeting will also be livestreamed on the Commission’s YouTube channel. Seating capacity is limited in the hearing room at the Civil Service Commission building where the Read the full article...
http://dlvr.it/SbdmSs

Flora Growth Signs Definitive Agreement to Acquire Franchise Global Health, a Prominent Pharmaceutical and Medical Cannabis Distributor with Principal Operations in Germany

FORT LAUDERDALE, Fla. & TORONTO--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) (“Flora'' or the “Company”), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that it has signed a definitive agreement to acquire 100% of Franchise Global Health Inc. (TSXV: FGH) (“FGH”), a multi-national operator in the medical cannabis and pharmaceutical industry, with principal operations in Germany. “Through this proposed acquisition, we are connecting our commercial infrastructure and medical cannabis product portfolio to the German and EU medical markets, while gaining direct access to European pharmaceutical distributions,” said Luis Merchan, Chairman and CEO of Flora Growth. “We believe Franchise will significantly increase our commercial international revenue and provide essential distribution to German pharmacies and a growing wholesale market.” FGH's German reportable segment achieved revenues of CA$30.1 million, gross profit of CA$2.1 million and net income of CA$0.4 million in the first half of 20221. FGH’s German businesses operate primarily in the export pharmaceutical and medical cannabis import and distribution markets, servicing 1,200 pharmacies in Germany and providing non-cannabis medical products to 28 additional countries. This acquisition is expected to accelerate Flora’s expansion into the European cannabis and pharmaceutical markets with prescription medicines and would provide the Company with immediate access to a wealth of knowledge and intellectual property that FGH has developed, including 41 registered cannabis strains in Colombia and the first registered cannabis seed bank in Copenhagen, Denmark housing 286 strains. The proposed acquisition would further allow Flora to expand its CBD business in Europe by utilizing FGH’s distribution and logistics capabilities. The combination of Flora and FGH is expected to deliver at least US$3.0 million of annualized cost synergies within the first year following the completion of the acquisition, primarily in the areas of reduced corporate administrative expenses. “Luis and I share the same vision of establishing a leading and sustainable cannabis business. Flora has the right platform to execute on this strategy through M&A and organic growth. We are excited to join forces,” says Clifford Starke, CEO and Executive Chairman of FGH. “Together we have a solid revenue base, a proven consumer packaged goods business that can be replicated in Europe, and a successful distribution network. Over the past few months, we have worked tirelessly to identify synergies, reduce costs, and build an industry-leading team.” About the Transaction On October 20, 2022, Flora and FGH entered into an Arrangement Agreement (the “Arrangement Agreement”) pursuant to which Flora intends to acquire all the issued and outstanding common shares of FGH by way of a statutory plan of arrangement (the “Arrangement”) under the Business Corporations Act (British Columbia). As consideration for the acquisition of 100% of the issued and outstanding FGH common shares, at the completion of the Arrangement, Flora will issue between 36,615,060 and 43,525,951 of its common shares, based upon a formula set forth in the Arrangement Agreement. In accordance with the terms set forth in the Arrangement Agreement, upon the completion of the Arrangement, all Flora common shares to be delivered to the former shareholders of FGH shall be restricted from being sold for a period of ninety (90) days following the completion of the Arrangement. In addition, Clifford Starke, the Chairman and Chief Executive Officer of FGH, shall have the right to name two designees to serve on Flora’s board of directors immediately following the closing of the Arrangement and Mr. Stake is currently expected to be one of such designees. Completion of the Arrangement is subject to certain closing conditions customary for transactions of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia and the approval of at least 66 2/3% of the votes cast by shareholders of FGH at a meeting of FGH shareholders. For further information on the Arrangement Agreement and the Arrangement, please refer to Flora’s Report on Form 6-K, filed today with the Securities and Exchange Commission. About Flora Growth Corp. Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information. About Franchise Global Health Inc. Franchise Global Health Inc. (“FGH”), through its subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industries, with principal operations in Germany and with operations, assets, strategic partnerships and investments internationally. FGH’s business objective is to develop a fully-integrated, leading European medical cannabis business, with the goal of providing high-quality pharmaceutical grade medical cannabis to distribution partners and, ultimately, to patients, at competitive prices. For more information, please visit www.franchiseglobalhealth.com or visit FGH’s SEDAR profile at www.sedar.com. Cautionary Statement Concerning Forward-Looking Statements This press release contains ‘‘forward-looking statements,’’ as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in Flora’s Annual Report on Form 20-F filed with the SEC on May 9, 2022, as amended, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that
http://dlvr.it/SbcmxK

Franklin Street Properties Corp. to Announce Third Quarter 2022 Results

WAKEFIELD, Mass.--(BUSINESS WIRE)--Franklin Street Properties Corp. (the “Company” or “FSP”) (NYSE American: FSP), a real estate investment trust (REIT), announced today that it expects to release its results for the third quarter 2022 after the market closes on Tuesday, November 1, 2022. The Company will hold a conference call/webcast with the investment community to discuss the results at 11:00 AM ET on Wednesday morning, November 2, 2022. To access the call, please dial 1-844-200-6205 and use access code 735617. Internationally, the call may be accessed by dialing 1-929-526-1599 and using access code 735617. To listen via live audio webcast, please visit the Webcasts & Presentations section in the Investor Relations section of the Company's website (www.fspreit.com) at least ten minutes prior to the start of the call and follow the posted directions. The webcast will also be available via replay from the above location starting one hour after the call is finished. This press release, along with other news about FSP, is available on the Internet at www.fspreit.com. We routinely post information that may be important to investors in the Investor Relations section of our website. We encourage investors to consult that section of our website regularly for important information about us and, if they are interested in automatically receiving news and information as soon as it is posted, to sign up for E-mail Alerts. About Franklin Street Properties Corp. Franklin Street Properties Corp., based in Wakefield, Massachusetts, is focused on infill and central business district (CBD) office properties in the U.S. Sunbelt and Mountain West, as well as select opportunistic markets. FSP seeks value-oriented investments with an eye towards long-term growth and appreciation, as well as current income. FSP is a Maryland corporation that operates in a manner intended to qualify as a real estate investment trust (REIT) for federal income tax purposes. To learn more about FSP please visit our website at www.fspreit.com.
http://dlvr.it/SbVG7l

Leafly’s 2nd Annual International Budtender Day Highlights the Importance of Cannabis’ Frontline Workforce with Exclusive Networking and Training Event in New Jersey

SEATTLE--(BUSINESS WIRE)--Today, Leafly Holdings, Inc. (“Leafly”), a leading cannabis discovery marketplace and resource, celebrates the 2nd Annual International Budtender Day with an exclusive networking and training event in Hoboken, NJ for current and aspiring budtenders - frontline cannabis retail workers - from new and up-and-coming East Coast. The event is in partnership with Business of Cannabis, a company that specializes in highlighting the companies, brands, people and trends driving the cannabis industry in North America. The only holiday that recognizes the often unrecognized workers in cannabis, Leafly’s International Budtenders Day celebrates the budtenders’ role in empowering customers with the knowledge they need to discover the benefits of cannabis, bringing awareness to an often overlooked profession that plays a crucial role in the success of the cannabis industry. During the event, Leafly will announce the two winners of a nationwide contest the company ran this month to recognize those who epitomize the ideal budtender: Mandi Drake, Verilife in Liverpool, NY Jacquelyn McTighe, Youngtown Curaleaf in Youngtown, Arizona Budtenders are the face of the cannabis industry. They are expected to understand cannabis and have the customer service skills necessary to explain the complexities of cannabis to a curious public. The position requires a passion for cannabis, exceptional knowledge of cannabis products and their effects, and strong customer service skills. As New York, Vermont, Connecticut, Rhode Island, and New Jersey continue to open their adult-use cannabis stores, demand for budtenders is rising across the East Coast. “The cannabis industry will never be as small as it is now and the demand for experienced budtenders will continue to grow. It is so rare to have an opportunity to shape an industry from its inception and this is an exciting time for new budtenders,” said Dr. Nick Jikomes, Leafly’s Director of Science and Innovation. “Leafly is the informed way to shop for weed and we believe knowledge is power. There is no better way to celebrate this holiday than by sharing information about this magical plant with up and coming budtenders seeking to join this emerging field.” Leafly offers budtenders cannabis online educational opportunities at no cost with thousands of educational articles covering every topic relevant to the industry. Two formal Leafly Learn courses are also available to budtenders employed by Leafly-subscribed retailers. Since launching the Leafly Learn platform in 2019, more than 13,000 budtenders from North America have enrolled in the program. The event in Hoboken - offered at no cost on a first come, first serve basis - features two training sessions led by Leafly experts: What Are Cannabis Strains? A chemistry-first approach on how different strains provide different effects. Three Ways to Shop for Weed: a deep-dive into cannabinoids, terpenes, and through a hands-on “terp bar” Members of the press in the New York City area are invited to attend the event upon request. About Leafly Leafly helps millions of people discover cannabis each year. Our powerful tools help shoppers make informed purchasing decisions and empower cannabis businesses to attract and retain loyal customers through advertising and technology services. Learn more at Leafly.com or download the Leafly mobile app through Apple’s App Store or Google Play.
http://dlvr.it/SbQ5ZB

OLCC Task Force on Cannabis-Derived Intoxicants and Illegal Cannabis Production

AGENDA Friday, October 21, 2022 11:00 AM – 1:00 PM Click here to join the meeting on Teams Or call in (audio only) +1 323-553-3576, Access Code: 865693614#
http://dlvr.it/SbMrpY

High Tide Announces Launch of Its NuLeaf Naturals Multicannabinoid Products in Ontario

CALGARY, Alberta--(BUSINESS WIRE)--High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, is pleased to announce that its Colorado-based subsidiary, NuLeaf Naturals (“NuLeaf”), has had its Full Spectrum Hemp Multicannabinoid oil and plant-based softgels with delta-9 tetrahydrocannabinol (“Delta 9”), cannabichromene (“CBC”), cannabidiol (“CBD”), cannabigerol (“CBG”) and cannabinol (“CBN”) listed for sale in Ontario. This listing comes after NuLeaf received approval from the Ontario Cannabis Store (“OCS”) to list these additional products in the OCS’s Fall Product call of 2022. The oil will be available in 1800 ml containers at a concentration of 12 mg for each of the listed five cannabinoids, while the plant-based softgels will be available in packages of 120, each softgel containing 3 mg of each of the five listed cannabinoids. “I am thrilled to finally share that the highly anticipated NuLeaf Naturals Multicannabinoid products are now available for all licensed cannabis retailers to stock in Ontario, Canada’s largest province, and should be available to consumers in the coming days at our Canna Cabana store network and through other licensed cannabis retailers. For some time now Canadian CBD customers have been reaching out to our team in the US asking when these products will become available north of the border; well, that wait is now over. While we are starting in Ontario, we look forward to launching these trail-blazing Multicannabinoid product lines in other Canadian provinces in the near future. I am pleased to announce that as of today NuLeaf has become High Tide’s first U.S.-based CBD subsidiary to have its products available for order in Canada through the OCS,” said Raj Grover, President and Chief Executive Officer of High Tide. “Since its founding in 2014, NuLeaf has been committed to creating the world’s highest quality cannabinoid products in their most pure and potent form. These Multicannabinoid oils and softgels contain a unique combination of five cannabinoids that is unparalleled in Canada. This one-of-a-kind product formulation sets NuLeaf apart from its competition and will help us continue to chip away at the illicit market share of CBD sales in Ontario and other Canadian provinces as these product launches continue.” added Mr. Grover. About NuLeaf Naturals Founded in 2014 in Denver, Colorado, NuLeaf Naturals is one of America’s leading cannabinoid companies. Since inception, NuLeaf has been committed to creating the world’s highest quality cannabinoid products in their most pure and potent form. NuLeaf’s products are produced at a cGMP-certified facility enabling them to manufacture groundbreaking cannabinoid formulations while reaching beyond the highest levels of regulatory compliance. Their cannabinoid products are sold direct-to-consumer from their website and are also available at bricks-and-mortar stores across the U.S. NuLeaf is committed to creating safe, consistent, and effective products and has proudly received over 25,000 verified 5-star customer reviews through its e-commerce platform. For more information about NuLeaf, please visit www.nuleafnaturals.com. ABOUT HIGH TIDE High Tide is a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets. The Company is the largest non-franchised recreational cannabis retail chain in Canada as measure by revenue, with 140 current locations spanning British Columbia, Alberta, Saskatchewan, Manitoba and Ontario. The Company is also North America’s first cannabis discount club retailer, under the Canna Cabana banner, which is the single-largest cannabis retail brand in Canada, with additional locations under development across the country. High Tide’s portfolio also includes retail kiosks and smart locker technology – Fastendr™. High Tide has been serving consumers for over a decade through its established e-commerce platforms, including Grasscity.com, Smokecartel.com, Dailyhighclub.com, and Dankstop.com and more recently in the hemp-derived CBD space through Nuleafnaturals.com, FABCBD.com, BlessedCBD.co.uk, BlessedCBD.de, and Amazon United Kingdom, as well as its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide was featured in the annual Report on Business Magazine’s ranking of Canada’s Top Growing Companies in both 2021 and 2022 and was named as one of the top 10 performing diversified industries stocks in the 2022 TSX Venture 50™. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain while providing a complete customer experience and maximizing shareholder value. For more information about High Tide, please visit www.hightideinc.com and its profile pages on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Neither the TSX Venture Exchange (the “TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones (including, without limitation, proposed acquisitions); the Company’s future growth prospects and intentions to pursue one or more viable business opportunities; the development of the Company’s business and future activities following the date hereof; expectations relating to market size and anticipated growth in the jurisdictions within which the Company and NuLeaf may from time to time operate or contemplate future operations; expectations with respect to economic, business, regulatory and/or competitive factors related to the Company and NuLeaf or the cannabis industry generally; the market for the Company and NuLeaf’s current and proposed product offerings, as well as the Company and NuLeaf’s ability to capture market share; the Company’s strategic investments and
http://dlvr.it/SbHWgM

OLCC Task Force on Cannabis-Derived Intoxicants and Illegal Cannabis Production

Task Force on Cannabis-Derived Intoxicants and Illegal Cannabis Production Law Enforcement Subcommittee AGENDA Thursday, October 20, 2022 10:00 AM – 12:00 PM Click here to join the meeting on Teams Or call in (audio only): +1 971-323-0147, Pass Code 776970576#  
http://dlvr.it/SbFH6W

Texas Original Releases Fast-Acting Sweet Dreams Gummy

AUSTIN, Texas--(BUSINESS WIRE)--Texas Original, Texas’ leading medical cannabis provider, announced its Sweet Dreams gummies are now available to qualifying patients statewide. Sweet Dreams gummies are specifically designed to help qualifying patients who suffer from insomnia, night terrors or restlessness as a result of various medical conditions. Patients can conveniently access the Sweet Dreams gummies from any of Texas Original’s 11 pickup locations and two permanent locations statewide—making up the largest footprint of any provider in Texas. With 450 mg of total cannabinoids per jar, the Sweet Dreams gummies are the best value for CBN gummies per milligram in the Texas medical cannabis market at $110 per jar. “When I sit down with patients to learn about their experiences with medical cannabis, I am overwhelmed by the relief they find from pain, insomnia and so many other symptoms that take a daily toll on their lives,” said Morris Denton, CEO of Texas Original. “With Sweet Dreams, we can specifically target one of the most essential parts of healing—a good night’s sleep. We’ve meticulously researched and tested these gummies to ensure patients get a consistent experience every time. They can rely on us to deliver the highest quality product on the market.” The dewberry-flavored Sweet Dreams gummies are available in 30-count packages formulated with 5 mg of CBN, 10 mg of THC and targeted rest terpenes in each gummy. Featuring nanoemulsion technology, Sweet Dreams are the only fast-acting CBN-based gummies available in the state. Patients can expect to feel the initial treatment effects as soon as 15 minutes after consumption—which is up to eight times faster than alternative CBN products in Texas. To learn whether you or a loved one qualifies for medical cannabis, visit www.texasoriginal.com/patients. About Texas Original Texas Original is the leading licensed medical cannabis producer in Texas, working alongside physicians to provide the highest quality cannabis medicine to patients and families seeking relief across the state. As fellow Texans, we are dedicated to representing the integrity of this great state with our commitment to quality, consistency and purity in every product we produce. We remain committed to advancing safe, legal access to this powerful medicine. Texas Original is headquartered in Austin, with delivery throughout the entire state. For more information, visit www.texasoriginal.com.
http://dlvr.it/SbDprJ

North America and South & Central America Medical Marijuana Market Report 2022: Increasing Approvals of Medical Marijuana Products Drives Growth – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "North America and South & Central America Medical Marijuana Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Application, Distribution Channel, and Regions" report has been added to ResearchAndMarkets.com's offering. The North America and South & Central America medical marijuana market was valued at US$ 6,645.16 million in 2021 and is projected to reach US$ 22,809.76 million by 2028; it is estimated to grow at a CAGR of 19.3% from 2022 to 2028. The report highlights trends prevailing in the market and factors driving the North America and South & Central America medical marijuana market. The market growth is attributed to increasing approvals of medical marijuana products and rising acceptance of the medicinal use of marijuana. However, the illegal use of cannabis as a street drug and misconceptions regarding marijuana limit the market growth. Medical marijuana is in its introduction stage in the medical health industry. It is a potent product accepted globally, where Chinese medicines are already being manufactured using these plants, and that too with a long history associated. Medical marijuana remains a significant influence in the healthcare industry to treat cases that are not entirely advisable with traditional medicines. Medical marijuana is just a typical marijuana plant that is processed to get the fundamental composition of cannabinoids, which is necessary to synthesize the product to be in use. Countries in North America have legalized the use and cultivation of medical cannabis. For instance, in 2012, Uruguay became the first country in the world to legalize the recreational use of cannabis. Similarly, in 2014, Brazil authorized the use of medical cannabis, and in 2016, it approved the import of medications based on CBD oil and products made from THC and marijuana flowers. In 2017, Peru approved a law regulating the medicinal and therapeutic use of cannabis and its derivatives. In 2018, the Government of Canada passed the Cannabis Act, which created a strict legal framework for controlling the production, distribution, sale, and possession of cannabis across Canada. In the US, as of February 2022, marijuana was legalized in 37 states and the District of Columbia. In the past few years, Mexico, Luxembourg, and Lesotho, among others, have joined the list of countries to legalize the use of marijuana for medical applications. However, despite widespread legalization of the use of cannabis, its legal cultivation and production have earlier been mostly limited to developing countries. In September 2019, the Ministry of Commerce, Agriculture, and Fisheries of Jamaica announced a partnership with Harvard International Phytomedicines and Medical Cannabis Institute (HIPI) to conduct research on the pharmacological benefits of marijuana. At the same time, Jamaica aims to capitalize on this partnership and utilize this opportunity to grow and develop its national marijuana industry. Moreover, the World Health Organization (WHO) states that ~80% of the world's population utilizes marijuana or cannabis for medical remedies. Therefore, the growing acceptance, cultivation, and production of medical marijuana in developing countries is contributing significantly to the growth of the North America and South & Central America medical marijuana market. Market Dynamics Market Drivers Increasing Approvals of Medical Marijuana Products Rising Acceptance of Medicinal Use of Marijuana in America Market Restraints Illegal Use of Cannabis as Street Drug and Misconceptions Regarding Marijuana Market Opportunities Increase in Job Opportunities in Marijuana Industry Future Trends Widespread Distribution of Medical Marijuana Key Topics Covered: 1. Introduction 2. North America and South & Central America Medical Marijuana Market - Key Takeaways 3. Research Methodology 4. North America and South & Central America Medical Marijuana - Market Landscape 5. North America and South & Central America Medical Marijuana - Key Market Dynamics 6. North America and South & Central America Medical Marijuana Market - Geographic Analysis 7. North America and South & Central America Medical Marijuana Market Analysis - By Product 8. North America and South & Central America Medical Marijuana Market - By Application 9. North America and South & Central America Medical Marijuana Market Analysis - By Distribution Channel 10. North America and South & Central America Medical Marijuana Market Revenue and Forecast To 2028 - Geographical Analysis 11. Impact of COVID-19 Pandemic on North America and South & Central America Medical Marijuana Market 12. North America and South & Central America Medical Marijuana Market - Industry Landscape 13. Company Profiles 14. Appendix Companies Mentioned Aphria, Inc. Aurora Cannabis Inc. Canopy Growth Corporation CanaQuest Medical Corporation GW Pharmaceuticals The Green Organic Dutchman Holdings Cannabis Science, Inc CANVORY Organigram Holdings Inc. Tikun Olam For more information about this report visit https://www.researchandmarkets.com/r/yb9h62
http://dlvr.it/Sb55Pj

Award-Winning Marijuana Brand Escape Artists Launches Pharmaceutical-Grade Cannabis Lotions Nationwide

DENVER--(BUSINESS WIRE)--Escape Artists, a leader in cannabis-infused wellness products, today announces the launch of its CBD Cream (shop.letsescape.com) with its signature lavender scent, now available online for purchase nationwide and in-room at the chic luxury boutique Thompson Denver. This potent and aromatic cream represents Escape Artists’ first product with national distribution. “We formulate our pharma-grade cream with strategic ingredients that enhance skin absorption at the cellular level and invite cannabinoids to penetrate deeply into targeted areas. Among other things, our innovative creams improve recovery from exercise-induced soreness,” said Dr. Kyle Hammerick, Ph.D., Chief Science Officer of Escape Artists and a 15-year veteran in pharmaceutical development and therapeutic medicine delivery. In addition to the CBD Cream’s ability to manage aches and pains from inflammation, its subtle scent of lavender nurtures a deep sense of relaxation and leaves a luxurious feeling on the skin without a waxy or greasy consistency. “Your appetite, sleep, mood, memory, immune system and much more are impacted by your body’s endocannabinoid system (ECS). The compounds found in hemp offer a variety of possible benefits as they work with the ECS, including restabilizing your body and helping you function in optimal ways,” said Dr. Kyle Hammerick. Escape Artists’ CBD Cream with Lavender (1400 mg, MSRP: $60) joins a portfolio of THC and CBD topicals, quick-dissolving sublingual Flights and other cutting-edge cannabinoid products. For more information, visit letsescape.com. About Escape Artists Escape Artists specializes in cannabis-infused products for everyday wellness and self-care. Using proven methodologies from the pharmacology and food science sectors, Escape Artists develops game-changing cannabinoid delivery models including transdermal topicals, fast-dissolving edibles and highly bioavailable tinctures. The brand sets the standard for accessible, easy-to-use products with consistent, reliable dosage control for medical applications and recreational use. Founded in 2017, the women-led company is one of the most widely distributed cannabis brands in Colorado and a category sales leader that is now expanding to markets across the United States. Escape To Now: letsescape.com
http://dlvr.it/Sb1rCt

SunOpta Announces Strategic Sale of Its Sunflower & Roasted Snacks Business to Pacific Avenue Capital

MINNEAPOLIS–(BUSINESS WIRE)–SunOpta Inc. (“SunOpta” or the “Company”) (Nasdaq:STKL) (TSX:SOY), a U.S.-based global pioneer fueling the future of sustainable, plant-based and fruit-based foods and beverages, today announced the sale of its sunflower business to Pacific Avenue Capital Partners (“Pacific Avenue”) for $16.0 million, subject to certain post-closing adjustments. The transaction closed on October 11, 2022. “This Read the full article...
http://dlvr.it/Sb1JLn

Cannabis Market by Product Type, Compound, Application and Region – Global Forecast to 2027 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Cannabis Market by Product Type (Flowers, Concentrates, Edibles, Topicals & Tinctures), Compound (THC-Dominant, CBD-Dominant, Balanced THC & CBD), Application (Medical, Recreational), and Region (North America, South America, Europe, RoW) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The global cannabis market is estimated to be valued at USD 27.7 billion in 2022 and is projected to reach USD 82.3 billion by 2027, recording a CAGR of 24.3% in terms of value. The market is driven by the rise in the use of cannabis for recreational and medical use. Moreover, there has been an increased legalization of cannabis in the US in states like Virginia in 2021 and Rhode Island in 2022 and in other countries like in Malta in 2021, and Thailand in 2018. The cannabis industry is growing rapidly and witnessing a double-digit growth rate globally. There are several major companies operating in the cannabis segment that dominate their respective markets. Thus, companies are competing to gain a significant market share. By application, the recreational segment is projected to grow at the highest CAGR during the forecast period Recreational cannabis demand is increasing continuously driven by Gen Z consumers. A small but encouraging portion of cannabis products are being sold to women due to a shift in public opinion, and this percentage is predicted to increase over time. Moreover, legalization has have led to a trend toward cannabis-related tourism, with locations producing novel holiday items to entice clients and increasing travel bookings to cannabis-legal destinations. By compound, the THC-dominant segment is estimated to account for the largest share THC strain is used for both medical and recreational applications, which increases its demand among manufacturers as well as consumers. Growing Together Research Inc., an Indiana-based biotechnology business, has created a new technique for genetically regulating the expression of Delta-9-THC in cannabis, including the capacity to boost cannabinoid levels in marijuana varieties grown for recreational or medical purposes. Moreover, other forms of THC, such as delta-8-THC, are gaining popularity in addition to the conventional version. The European region is projected to grow at the highest CAGR during the forecast period The market in Europe is majorly driven by the awareness of medical benefits of cannabis in the region coupled with the healthcare system present in several European countries that covers the health expenditure of most patients in these regions. As the legalization of cannabis in European countries is at a nascent stage, this creates a considerable opportunity for companies to establish themselves in the region. Since the beginning of 2019, the European cannabis market has witnessed multiple mergers and acquisitions involving companies focused on medical cannabis. Like in the starting of 2021 medical cannabis firm GW Pharmaceutical was acquired by Jazz Pharmaceutical for USD 6.15 Billion. Market Dynamics Drivers Rising Cannabis Demand for Medicinal Applications Legalization of Cannabis and Rise in Social Acceptance Growth in R&D Activities and Technological Advancements to be Precursors for Cannabis Business Rising Global Cannabis Sales Helping Online Retailers Expand Restraints Complex Regulatory Structure for Use of Cannabis Problems Associated with High Dose of Cannabis Consumption Stigmatization of Cannabis Market Profit Margins of Manufacturers Shrinks as Cannabis Prices Fall Opportunities Emergence of Cannabis Legalization in Asia-Pacific Edibles, Led by Gummies and Chocolates, to Present Additional Growth Opportunities for Cannabis Business Inorganic Growth Strategies Adopted by US Cannabis Companies Challenges Intensive Water Consumption and Inability to Maintain Consistency During Cannabis Cultivation Cannabis-Producing Businesses Face Financing Difficulties in US Advertising and Marketing Restrictions in US Supply Chain Challenges Associated with Cannabis in US Companies Mentioned Aurora Cannabis Inc. Cannabliss Organic LLC Canopy Growth Corporation Connected Cannabis Co. Cresco Labs Curaleaf Ecofibre Limited Green Thumb Industries Henry's Original HEXO Corp. Indiva Justice Cannabis Co. Maricann Group Inc. Medical Marijuana, Inc. Medmen Organigram Holdings Inc. Satipharm Stenocare TerrAscend The Cronos Group Tikun Olam-Cannbit Pharmaceuticals Ltd. Tilray Trulieve Unrivaled Brand Inc. Verano Village Farms International Inc. VIVO Cannabis Inc. For more information about this report visit https://www.researchandmarkets.com/r/oc9tbx
http://dlvr.it/SZyZWD

Congressman Blumenauer Applauds Biden’s Actions to Pardon Prior Marijuana Offenses

Announcement comes after Blumenauer, Lee called on Biden to Pardon Federal Cannabis Offenses in 2021 DISTRICT OF COLUMBIA:Today, Congressman Earl Blumenauer, Founder and Co-Chair of the Congressional Cannabis Caucus released the following statement welcoming President Biden’s announcement to pardon all simple, non-violent cannabis offenders: “Today, President Biden took an important step in the fight to Read the full article...
http://dlvr.it/SZhSXZ

Global Biocomposites Markets Report 2023-2033 with Profiles of 150+ Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Global Market for Biocomposites 2023-2033” report has been added to ResearchAndMarkets.com’s offering. Biocomposites are generally referred to as composites with either reinforcement or matrix derived from natural sources, or encompassing both (full biocomposites). Biocomposites are produced from naturally-renewable and abundant precursor feedstocks, and possess properties equivalent, on a weight basis, to their Read the full article...
http://dlvr.it/SZc71T

Latin America Green Data Center Market Outlook and Forecast 2022-2027 – Larger Colocation and Hyperscale Data Center Operators Driving the Market – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Latin America Green Data Center Market - Industry Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. Market is expected to reach a value of $825 million in 2027, from $455 million in 2021, growing at a CAGR of 10.4% The region's increasing digitalization, previously underserved status, the shift to the cloud, the growing popularity of IoT and big data, the emergence of 5G networks, the COVID-19 pandemic, and the demand for high-speed streaming of online entertainment content are some of the major factors driving the growth of the Latin American data center market. With the tremendous growth in data center deployment, the green data center market is becoming a leading trend in data center development and operations. LATIN AMERICA GREEN DATA CENTER MARKET TRENDS AND DRIVERS Innovations in Power and Cooling Technology are Driving the Market for Green Development Innovations in data center power technology include the adoption of lithium-ion and smart grid UPS systems and the adoption of DRUPS systems in Latin America. Fuel cells'-based power backup is also expected to make an entry into the Latin American market in the long term, driving down investments in inefficient diesel generators and driving the market for efficient products. A tropical test bed is currently in Singapore's testing phase, making data centers more efficient in a tropical climate. If successful, this can also positively impact the Latin American market and further bring down the PUE of facilities. Free cooling is also being adopted by data center operators in facilities in countries like Brazil, Chile, Argentina, and the Caribbean, at least partially. For instance, Equinix uses free cooling in its SP3 data center in Sao Paulo. Government push toward Sustainability Various Latin American governments, including those of Chile, Brazil, and Uruguay, are actively working towards increasing the adoption of renewable energy in the country. The Development Bank of Latin America has approved a loan of $300 million to Uruguay to strengthen its electricity grid and modernize it, driven by the government. Deployment of Modular Data Centers and Sustainable Material gathering steam The cost of operating a modular data center is around 30% less than that of a traditional data center facility, making it an attractive proposition in Latin America and driving the growth of the Latin America modular data center market, owing to many operators having limited funds for data center development. The environmental impact of modular data center deployment is also lower since it entails lower or no usage of concrete can be constructed in a phased manner and eliminates the need for additional labor. Plant-based and other sustainable materials such as wood, hemp, and Mycelium, which can revolutionize the construction process for data centers, are also being adopted by data center operators. GEOGRAPHICAL ANALYSIS Among the Latin American countries, Brazil, Columbia, Argentina, and Paraguay are among the countries that have actively adopted renewable energy for most of their energy requirements. Countries such as Mexico are also expected to ramp up their renewable energy adoption in the coming years, especially owing to worldwide and regional policies promoting the use of renewable energy. In Mexico, just over 30% of the energy mix is renewable. In Argentina, around 26 large-scale renewable energy projects were commissioned in 2021, adding over 1GW of renewable energy. The energy capacity increased approximately 24% in 2021 compared with 2020. VENDOR ANALYSIS Larger colocation and hyperscale data center operators driving the market Hyperscale operators like Google and Microsoft actively drive renewable energy adoption in Latin America. For instance, in December 2021, Google launched its cloud region in Santiago, powered by solar energy procured from ACCIONA Energia's El Romero photovoltaic plant. Colocation operators such as ODATA and Scala Data Centers are active adopters of renewable energy in Latin America. For instance, Scala Data Centers signed a Power Purchase Agreement (PPA) with ENGIE Brasil Energia in 2021 to supply over 1,600 GWh of renewable energy to the operator until 2033. Some major renewable energy producers and suppliers in the Latin American market include Enel Green Power, Engie, GreenYellow, and The AES Corporation. KEY HIGHLIGHTS OF THE INDUSTRY Policy drivers and regulations such as The Paris Agreement, the RE100, and certifications such as Leadership in Energy and Environmental Design (LEED) and ISO50001 drive Latin America green data center market development market. Significant contributors to green data center development in Latin America include Brazil, Chile, Argentina, and Paraguay, among others. Data center operators and governments are working towards adopting renewable energy and other measures. Hyperscale operators in Latin America, including Google, Microsoft, Amazon Web Services, and Huawei Technologies, are driving the market in terms of sustainable investment and innovative technologies. Prominent Data Center Investors Ascenty Ava Telecom Amazon Web Services (AWS) Claro Equinix Google HostDime Huawei Technologies KIO Networks Microsoft ODATA Oracle Scala Data Centers Renewable Energy Providers Acciona Energia EDP Renewables Enel Green Power Engie Elera Renovaveis Faro Energy GreenYellow HDF Energy Iberdrola Mainstream Renewable Power RZK Energia Shell The AES Corporation TotalEnergies Key Topics Covered: 1 Research Methodology 2 Research Objectives 3 Research Process 4 Scope & Coverage 4.1 Market Definition 4.2 Base Year 4.3 Scope of the Study 4.4 Market Segments 5 Report Assumptions & Caveats 5.1 Key Caveats 5.2 Currency Conversion 5.3 Market Derivation 6 Market at a Glance 7 Premium Insights 7.1 Key Highlights 7.2 Key Market Trends 7.3 Geographical Analysis 7.4 Vendor Analysis 8 Introduction 8.1 Overview 8.1.1 Sustainable Data Center Development 8.2 Green Data Center Metrics 8.3 Power Usage Effectiveness (Pue) 8.3.1 Key 8.4 Policy Drivers 8.4.1 the Paris Agreement & the Science Based Targets Initiative (Sbti) 8.4.2 Long Duration Energy Storage (Ldes) Council 8.4.3 Re100 8.4.4 Circular Economy 8.5 Energy Certifications 8.6 Efficiency in It Infrastructure 8.6.1 E-Waste Disposal 9 Market Opportunities & Trends 9.1 Innovative Data Center Power Technologies 9.1.1 Adoption of Advanced Ups Batteries 9.1.2 Software-Defined Data Centers & Ai in Power Monitoring 9.1.3 Microgrids 9.2 Sustainable Innovations in Data Center Power Technology 9.2.1 Eco-Diesel Generators 9.2.2 Natural Gas Generators 9.2.3 Fuel Cells 9.2.4 Hydrotreated Vegetable Oil (Hvo) Fuel 9.2.5 Nuclear Energy Generation 9.2.6 Other Innovations 9.3 Innovative Data Center Cooling Technologies 9.3.1 Tropical Data Center Test Bed 9.3.2 Free Cooling 9.3.3 Underwater Data Centers 9.3.4 Floating Data Centers 9.3.5 Other Innovative Cooling Technologies 9.4 Ai & Hpc Applications Driving Liquid Immersion & Direct-To-Chip Cooling Adoption 9.4.1 Ai Initiatives in Latin America 9.5 Renewable Energy Initiatives 9.6 Growth in Data Centers Targeting a Pue of < 1.5 9.7 Adoption of Advanced It Infrastructure 9.7.1 Converged & Hyperconverged Infrastructure 9.7.2 Arm-Based Servers 9.7.3 Server Virtualization 9.8 Government Push for Green Data Center Development 10 Market Growth Enablers 10.1 Renewable Energy Initiatives by Hyperscale & Cloud Operators 10.2 Renewable Energy Initiatives by Colocation Operators 10.3 Automation & Intelligent Monitoring Solutions 10.4 Deployment of Modular Data Centers 11 Market Restraints 11.1 Rising Carbon Emissions from Data Centers 11.2 Water Consumption by Data Centers 11.3 Lack of Skilled Data Center Professionals 11.4 Location Constraints on Green Data Centers 12 Market Landscape 12.1 Market Overview 12.2 Investment: Market Size & Forecast 12.3 Power Capacity: Market Size & Forecast 12.4 Five Forces Analysis 13 Infrastructure 13.1 Market Snapshot & Growth Engine 13.2 Electrical Infrastructure 13.3 Mechanical Infrastructure 13.4 General Construction 14 Electrical Infrastructure 14.1 Market Snapshot & Growth Engine 14.2 Ups Systems 14.3 Generators 15 Mechanical Infrastructure 15.1 Market Snapshot & Growth Engine 15.2 Cooling Systems 15.3 Racks 16 Cooling System 16.1 Market Snapshot & Growth Engine 16.2 Crac & Crah Units 16.3 Chiller Units 16.4 Cooling Towers, Condensers & Dry Coolers 16.5 Economizers & Evaporative Coolers 17 General Construction 17.1 Market Snapshot & Growth Engine 17.2 Core & Shell Development 17.3 Mep & Architectural Design Services 17.4 Physical Security & Fire Safety Systems 17.5 Dcim/Bms Solutions For more information about this report visit https://www.researchandmarkets.com/r/8l0iwt
http://dlvr.it/SZZNw1

Enable Steps Up Global Expansion with New Sydney-Based Office to Strengthen its Position as the Category Leader in Rebate Management

SAN FRANCISCO & SYDNEY--(BUSINESS WIRE)--Enable, the collaborative rebate management platform, is pleased to announce the opening of a new office in Sydney CBD. The expansion allows Enable to build on its global presence to better serve the Australian market and support its growing team with a world class facility. The expansion comes one year after the opening of Enable’s Toronto, ON location. The Sydney office will be the fourth location joining the Toronto, San Francisco, CA (corporate headquarters) and Stratford-upon-Avon, UK offices. Enable is on a trajectory to more than double revenue by year end and ultimately put a stake in the rebate management category. With 400 employees, up from 100 employees two years ago and thousands of companies using Enable across North America, Europe, and Australia, the company will continue to support the imperative need for efficient rebate management and rebuilding trust between trading partners. “We’ve been seeing a lot of interest in the region, and as we started to win more customers it made sense to expand our area of influence into the APAC region,” said Andrew Butt, Co-founder & CEO of Enable. “There is tremendous growth opportunity not just in the Australian market but throughout APAC countries. This is our first step forward to address this exciting new market and supporting our growing list of customers in the region.” The company is on a mission to enable trusted trading relationships throughout the supply chain. Enable’s platform allows companies to better manage rebate complexity and to author, agree upon, execute, and track the progress of all trading deals in one place. In today’s climate, efficient management of rebate complexity has become a major opportunity for manufacturers, distributors and retailers alike to boost sales and increase profits. “Tremendous forces are at work on the supply chain,” said Butt. “Maintaining relationships with trading partners is more critical now than ever before. Rebates are a strategic solution that helps to keep those relationships healthy, ensuring that everyone is aligned on goals with incentives to make them happen.” ABOUT ENABLE Enable helps manufacturers, distributors, and retailers take control of their rebate programs and turn them into an engine for growth. Starting with finance and commercial teams, Enable helps you better manage rebate complexity with automated real-time data and insights, accurate forecasting and stronger cross-functional alignment. This lets you — and everyone in your business — know exactly where you are with rebates. Then you can extend Enable externally to suppliers and customers, setting them up with one collaborative place to author, agree upon, execute on, and track the progress of deals.
http://dlvr.it/SZYyN8

Global Medical Marijuana Market Trends/Analysis Report 2022: A $65.8 Billion Industry by 2030 – Rapid Adoption of Cannabis in Therapeutic Applications – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Medical Marijuana Market Size, Share & Trends Analysis Report by Product Type (Flower, Oil & Tinctures), by Application (Chronic Pain, Arthritis, Migraine, Cancer, Diabetes, AIDS, Epilepsy, Parkinson's Disease), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global medical marijuana market size is expected to reach USD 65.8 billion by 2030 and is expected to expand at a CAGR of 21.6% The major factors attributed to the industry growth are the rapid adoption of cannabis in therapeutic applications and a surge in the number of countries legalizing the usage of medical marijuana. As per numerous studies, cannabis has shown positive results in the treatment of chronic diseases. Thus, with the growing penetration of chronic disease throughout the globe, the industry is expected to see a steep rise in demand. For instance, as per the data released by the WHO, the chronic disease burden was expected to reach 57% by 2020. The growing research and development activities in the industry are also expected to drive the growth in demand. Additionally, various factors such as a rise in disposable income, increasing social acceptance of cannabis, and growth in awareness regarding the benefits of the product, along with improvements in intellectual property rights of cannabis are some of the major factors that are expected to fuel the growth of the industry. Key players are coming together on strategic initiatives such as mergers & acquisitions, collaborations, partnerships, funding & investments, and innovative product developments & launches to expand their expertise & product portfolio. This also fuels the industry's growth. For instance, in March 2021, Germany's largest pharmaceutical company, Stada entered the medical marijuana market by launching its two flower products, and further, the company has plans to offer five flower products along with three extracts with different compositions of CBD and THC. One of the major factors that restrict industry growth is the strict regulation policy. To date, FDA has not allowed the marketing usage of cannabis for the treatment of any disease or condition. Although, the organization has approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These permitted drug products are only available with a prescription from a licensed healthcare provider. Medical Marijuana Market Report Highlights The market size is anticipated to be valued at USD 65.8 million by 2030, owing to the growing legalization of medical marijuana in various countries In 2021, the oil and tinctures segment dominated the market owing to its growing medical usage for the treatment of chronic pains, cancer, neurological disorders, and others Chronic pain segment dominated in 2021. The growing number of clinical trials with marijuana to treat neuropathic and chronic pain is one of the key indicators, which highlights the rising usage of cannabis in pain management over the coming few years North America dominated in 2021 owing to the presence of major players, the increasing rate of cannabis legalization in the U.S., and the launch of new products Company Profiles Tilray Aurora Cannabis Canopy Growth Corporation Aphria, Inc. Maricann Group, Inc. Tikun Olam, Ltd. MedReleaf. Corp. GW Pharmaceuticals plc. Cannabis Sativa, Inc. Medical Marijuana, Inc. Key Topics Covered: Chapter 1 Methodology and Scope Chapter 2 Executive Summary 2.1 Medical Marijuana Market Outlook, By Revenue (USD Million) Chapter 3 Medical Marijuana Market Variables, Trends and Scope 3.1 Penetration & Growth Prospect Mapping 3.2 Product Pipeline Analysis, by Stage 3.3 Technology Overview 3.3.1 Technology timeline 3.4 Regulatory Framework 3.5 Market Dynamics 3.5.1 Market driver analysis 3.5.2 Market restraint analysis 3.6 Medical Marijuana Market Analysis Tools 3.6.1 Industry analysis - Porter's 3.6.2 PESTEL Analysis 3.6.3 Global Marijuana Demand-Supply Analysis 3.6.4 Global Marijuana Trade Route 3.6.5 Patient Pool Analysis Chapter 4 Medical Marijuana Market: Product Type Estimates & Trend Analysis 4.1 Definitions & Scope 4.2 Medical Marijuana Market Share by Product Type 4.3 Segment Dashboard 4.4 Flower 4.4.1 Flower market estimates and forecasts, 2017 - 2030 (USD Million) 4.5 Oil & Tinctures Chapter 5 Medical Marijuana Market: Application Estimates & Trend Analysis 5.1 Definitions & Scope 5.2 Medical Marijuana Market Share by Application 5.3 Segment Dashboard 5.4 Cancer 5.4.1 Cancer market estimates and forecasts, 2017 - 2030 (USD Million) 5.5 Chronic Pain 5.6 Depression & Anxiety 5.7 Arthritis 5.8 Diabetes 5.9 Glaucoma 5.10 Migraines 5.11 Epilepsy 5.12 Multiple Sclerosis 5.13 AIDS 5.14 Amyotrophic Lateral Sclerosis 5.15 Alzheimer's Disease 5.16 Post-Traumatic Stress Disorder (PTSD) 5.17 Parkinson's Disease 5.18 Tourettes Chapter 6 Medical Marijuana Market: Regional Estimates & Trend Analysis, by Product 6.1 Market Size, & Forecasts, and Trend Analysis, 2017 to 2030: 6.1.1 U.S. 6.1.1.1 Market estimates and forecasts, by product type, 2017 - 2030 (USD Million) 6.1.1.2 Market estimates and forecasts, by application 2017 - 2030 (USD Million) 6.2.1 Canada 6.3.1 Germany 6.4.1 U.K. 6.5.1 Italy 6.6.1 Poland 6.7.1 Czech Republic 6.8.1 Switzerland 6.9.1 Croatia 6.10.1 Netherlands 6.11.1 Spain 6.12.1 China 6.13.1 Japan 6.14.1 India 6.15.1 Thailand 6.16.1 Australia 6.17.1 New Zealand 6.18.1 Uruguay 6.19.1 Colombia 6.20.1 Brazil 6.21.1 Mexico 6.22.1 Africa Chapter 7 Competitive Landscape 7.1 Company Overview 7.2 Financial Performance 7.3 Product Benchmarking 7.4 Strategic Initiatives For more information about this report visit https://www.researchandmarkets.com/r/wol6pb
http://dlvr.it/SZVhhF

Aelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces today that Pier Vincenzo Piazza, CEO of Aelis Farma, has received the Entrepreneur of the Year 2022 award from auditing and consulting firm Ernst and Young, in the “Scale-Up” category. For the last 30 years, this Entrepreneur of the Year award highlights men and women who create wealth and employment in France. The Scale-Up of the Year award recognizes entrepreneurs embarked on a major acceleration phase of their activity and capable of becoming the next French unicorns. For this 30th edition, the Entrepreneur award highlighted almost 300 contenders in eight major French regions: Est, Ile-de-France, Sud-Est, Occitanie, Nouvelle-Aquitaine, Nord de France, Ouest and Auvergne-Rhône-Alpes. “It is a genuine honor to receive this award that we owe to the immense work undertaken by Aelis Farma’s teams. It is to them that I dedicate this award, congratulating and thanking them for making this collective success possible. Thanks to their exemplary commitment and expertise, Aelis Farma is seeing rapid and solid growth enabling it to position itself today as one of the most innovative companies in the field of brain diseases, addressing major health issues characterized by substantial unmet medical needs such as cannabis addiction and cognitive disorders associated with Down syndrome”, commented Pier Vincenzo Piazza. *** About AELIS FARMA Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). These new molecular entities hold great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was Director of the Inserm Magendie Neurocenter in Bordeaux. For these discoveries, Dr. Piazza was awarded the Inserm Grand Prix and the Grand Prix of Neurology of the French Academy of Sciences, which are among the most prestigious French prizes in medicine and neurology. Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB1-SSi for the treatment of other diseases associated with a dysregulation of the activity of the CB1 receptor. AEF0117, which targets the disorders due to excessive cannabis use (addiction and psychosis), has shown indications of efficacy in a phase 2a clinical trial and has entered a phase 2b clinical trial in the United States in Q2 2022. Aelis Farma has an exclusive option-license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma received $30 million (option payment). If Indivior exercises the license option at the end of the phase 2b, Aelis Farma will receive a $100 million license fee (potentially in 2024) and up to $340 million in additional payments contingent on the achievement of development, regulatory and commercial milestones as well as, royalties on net sales of AEF0117 ranging between 12% and 20%. AEF0217, which targets various cognitive disorders including those associated with Down syndrome, has finished recruitments of its phase 1 program in healthy volunteers and will start in Q4 2022 a phase 1/2 study in Down syndrome subjects. This compound has undergone an extensive preclinical proof-of-concept program using highly innovative assessing cognitive functions. In this context, AEF0217 has demonstrated its ability to completely reverse cognitive deficits observed in several animal models of neurodevelopmental disorders, such as Down syndrome and Fragile X syndrome, as well as in models of certain cognitive deficits associated with aging. Based in Bordeaux, within the Magendie Neurocenter, Aelis Farma has a team of 23 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement. For more information: www.aelisfarma.com About the global EY organization The global EY organization is a leader in assurance, tax, transaction and advisory services. We leverage our experience, knowledge and services to help build trust and confidence in the capital markets and in economies all over the world. We are ideally equipped for this task — with well trained employees, strong teams, excellent services and outstanding client relations. Our global purpose is to drive progress and make a difference by building a better working world — for our people, for our clients and for our communities. The global EY organization refers to all member firms of Ernst & Young Global Limited (EYG). Each EYG member firm is a separate legal entity and has no liability for another such entity’s acts or omissions. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. For more information about our organization, please visit ey.com. For more information on the EY Entrepreneur of the Year Awards: https://www.ey.com/fr_fr/prix-de-l-entrepreneur-de-l-annee ISIN: FR0014007ZB4 Ticker: AELIS B Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release are forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance or achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and detailed in Chapter 3 "Risk Factors" of Aelis Farma's registration document approved by the Autorité des marchés financiers on 14 January 2022 under number I.22-003. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
http://dlvr.it/SZT89H